Dalya Gartzman
Chief Executive Officer Renasis Bio
Dalya is a mathematician and AI expert turned biotech entrepreneur. She holds an MSc in mathematics and bioinformatics and has spent her career leading AI products from idea to market across multiple early-stage startups.
Beyond her technical work, she is a longtime mentor and community leader in tech.
After years of building AI for complex real-world systems, Dalya turned her focus to biology – co-founding Renasis Bio, an AI-driven platform for RNA-targeting drug discovery, where she now serves as CEO. The company’s long-term ambition is to modulate the full landscape of RNA regulation, expanding the frontier of human health.
Seminars
Identifying RNA targets that are both biologically meaningful and chemically tractable remains one of the biggest bottlenecks in RNA-targeted drug discovery. Many RNA regions are capable of binding small molecules, but only a subset controls diseaserelevant biology in a way that can support a therapeutic hypothesis.
Join RNA biologists, screening scientists, translational researchers, and discovery
teams to explore practical strategies for:
- Identifying which RNA transcripts, structures and regulatory elements are suitable for small-molecule intervention
- Moving beyond one-at-a-time target discovery with scalable screening and functional assay approaches
- Using chemical probing to distinguish dynamic RNA structures from functionally important conformational switches
- Matching each RNA target to the most appropriate therapeutic hypothesis, from splice modulation to direct binding, degradation or translational inhibition
- Learning from screening approaches that failed to generate actionable targets, functional hits or reliable discovery decisions
